Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 19 |
| Active Pipeline (Recruiting Now) | 12 (11) |
| Completed vs Stopped Early | 1 / 2 (10.5%) |
| Median Closed Actual Enrollment | 11 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Washington University and Siteman Cancer Center | Saint Louis, MO | 5 |
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT03266627 | Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection | Phase II | RECRUITING |
| NCT03266640 | Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV) | Phase II | RECRUITING |
| NCT03266653 | EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the New York Medical College Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.